Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 113.3% in June

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 441,157 shares, an increase of 113.3% from the June 15th total of 206,873 shares. Approximately 7.8% of the shares of the stock are sold short. Based on an average daily volume of 302,873 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ARMP. Bank of America Corp DE boosted its position in shares of Armata Pharmaceuticals by 233.2% during the first quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock valued at $120,000 after buying an additional 8,198 shares during the period. Sei Investments Co. bought a new stake in shares of Armata Pharmaceuticals during the 1st quarter worth approximately $760,000. Madison Asset Management LLC bought a new stake in shares of Armata Pharmaceuticals during the 1st quarter worth approximately $21,583,000. Millennium Management LLC purchased a new position in Armata Pharmaceuticals during the 4th quarter valued at $164,000. Finally, 683 Capital Management LLC bought a new position in Armata Pharmaceuticals in the 4th quarter valued at $878,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Stock Performance

ARMP stock traded up $0.07 during mid-day trading on Wednesday, reaching $3.99. 139,821 shares of the stock traded hands, compared to its average volume of 83,569. Armata Pharmaceuticals has a one year low of $2.31 and a one year high of $16.34. The stock has a market capitalization of $146.47 million, a PE ratio of -0.51 and a beta of 1.26. The business has a 50-day moving average price of $7.22 and a two-hundred day moving average price of $8.39.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The firm had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $0.74 million. On average, equities analysts expect that Armata Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.